Business Context and Reporting Period
Company: Metagenomi Therapeutics, Inc. (MGX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Metagenomi is a precision genetic medicines company developing curative therapeutics using a proprietary metagenomics-derived genome editing toolbox. The company focuses on in vivo gene editing for its wholly-owned pipeline and out-licensing technology for ex vivo cell therapies. As of June 30, 2025, the company had 37,533,136 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Collaboration Revenue | $8,513 | $12,640 | N/A |
| Total Operating Expenses | $29,500 | $61,447 | N/A |
| Net Loss | $(19,908) | $(44,947) | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.54) | $(1.21) | N/A |
| Cash, Cash Equivalents & Marketable Securities | N/A | N/A | $205,000 |
| Accumulated Deficit | N/A | N/A | $(267,949) |
| Net Cash Used in Operating Activities | N/A | $(44,093) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $11.5 million (57%) for the three months ended June 30, 2025, compared to the prior year period. This was primarily due to the termination of the Moderna collaboration agreement in April 2024, which eliminated $15.9 million in revenue recognized in the prior year quarter. This decrease was partially offset by a $5.1 million increase in revenue from the Ionis collaboration.
- Expense Reduction: Total operating expenses decreased by $7.4 million (20%) for the three months ended June 30, 2025, compared to the prior year. Research and development expenses dropped $5.8 million, driven by reductions in supplies/services, employee-related costs, and stock-based compensation.
- Investment Loss: The company recognized a $1.3 million loss related to the change in fair value of its long-term investment in Affini-T Therapeutics, Inc., reducing the investment's carrying value to $0.0 million as of June 30, 2025.
- Liquidity Position: Cash, cash equivalents, and available-for-sale marketable securities totaled $205.0 million as of June 30, 2025, down from $248.4 million at year-end 2024, reflecting operating cash burn and net maturities of securities.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash and marketable securities ($205.0 million) are sufficient to fund operations for at least the next 12 months from the date of issuance (August 2025).
- Pipeline Progress:
- MGX-001 (Hemophilia A): The company plans to conduct pre-IND meetings in the second half of 2025 and submit IND/CTA applications in 2026. Recent non-human primate studies using a bioengineered FVIII construct showed higher-than-expected activity.
- Ionis Collaboration: All four Wave 1 targets (cardiometabolic focus) achieved in vivo rodent proof-of-concept in 2024. The company plans to nominate 1-2 development candidates in 2025 and initiate IND-enabling activities in 2026.
- Affini-T Collaboration: Affini-T exercised an option for a non-exclusive license in April 2025, triggering a $0.3 million payment.
- Capital Markets: The company has an effective shelf registration statement and an "At-The-Market" (ATM) sales agreement with Jefferies LLC for up to $75.0 million. No shares have been sold under the ATM agreement as of June 30, 2025.
- Legal Contingencies: A securities class action lawsuit (Vreeland v. Metagenomi Inc. et al.) was filed in September 2024 alleging misleading statements regarding the Moderna collaboration. The company filed a motion to dismiss in May 2025, which is pending. The company cannot currently estimate the likelihood of loss.
- Personnel Changes: In July 2025, the Chief Medical Officer tendered her resignation, effective August 22, 2025. The Board also formed a new Research and Development Committee.
Investor Verification Checklist
- Revenue Sustainability: Verify the timeline for recognizing remaining deferred revenue from the Ionis agreement ($28.6 million allocated to remaining performance obligations) and the potential for new collaboration deals to replace lost Moderna revenue.
- Cash Burn Rate: Monitor the quarterly net cash used in operating activities ($44.1 million for the first half of 2025) against the $205.0 million liquidity runway to assess the need for additional financing before the 12-month horizon.
- Investment Valuation: Confirm the status of the Affini-T investment, which was written down to zero, and assess the impact of the $1.3 million fair value loss on future financial statements.
- Legal Exposure: Track the status of the Vreeland securities litigation and the motion to dismiss, as an adverse outcome could result in significant damages.
- Development Milestones: Watch for updates on the MGX-001 IND submission timeline (targeted for 2026) and the nomination of development candidates from the Ionis Wave 1 targets in 2025.